A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload.

NCT00390858 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Transfusional Iron Overload
β-thalassemia Major
Pediatric Rare Anemia

Interventions

DRUG: Deferasirox

Sponsor

Novartis Pharmaceuticals